Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis

Reuters

2025/06/03

Chemomab <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis

Chemomab Therapeutics Ltd. has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis $(PSC.AU)$, with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462119-en) on June 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540934779"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540934779\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540934779?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540934779","market":"us","top_or_hot":-1,"title":"Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chemomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMMB\">Chemomab Therapeutics Ltd.</a> has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis <a href=\"https://laohu8.com/S/PSC.AU\">$(PSC.AU)$</a>, with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462119-en) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-03 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chemomab <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CMMB\">Chemomab Therapeutics Ltd.</a> has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis <a href=\"https://laohu8.com/S/PSC.AU\">$(PSC.AU)$</a>, with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462119-en) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL2vkPky:1","article_id":"2540934779","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540934779","pubTimestamp":1748952049,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis. Chemomab Therapeutics Ltd. has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis , with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","CMMB":"Chemomab Therapeutics Ltd."},"translate_title":"Chemomab Therapeutics在中国和俄罗斯获得Nebokitug新专利，巩固其在治疗原发性硬化性胆管炎方面的地位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMMB":0.9,"NDAQ":0.9},"content_text":"Chemomab Therapeutics Secures New Patents for Nebokitug in China and Russia, Strengthening Position in Treating Primary Sclerosing Cholangitis\n    \n\nChemomab Therapeutics Ltd. has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis $(PSC.AU)$, with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9462119-en) on June 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}